Literature DB >> 7011057

Pulmonary injury and prostaglandin production during endotoxemia in conscious sheep.

R H Demling, M Smith, R Gunther, J T Flynn, M H Gee.   

Abstract

Prostaglandins F2 alpha, E2, and I2 (as 6-keto-PGF1 alpha) and TxA2 (as TxB2) were measured by radioimmunoassay in plasma and lymph from 12 conscious sheep with chronic lung lymph fistulas given Escherichia coli endotoxin (2-10 micrograms/kg) and followed for 24 h. Endotoxin produced a two-phase pulmonary injury. Phase 1 was characterized by transient severe pulmonary hypertension and increased lymph flow rate (QL). Plasma and lymph PGF2 alpha concentrations increased from base-line values of 0.13 +/- 0.08 and 0.30 +/- 0.10 ng/ml to 0.96 +/- 0.37 and 2.8 +/- 0.80 ng/ml, respectively. Values for TxB2 increased from 0.7 +/- 0.1 to 5.5 +/- 1.1 ng/ml in lymph and to 3.2 +/- 0.6 in plasma. Plasma PGI2 increased from 0.48 +/- 0.29 to 4.97 +/- 1.21 ng/ml and lymph PGI2 from 1.80 +/- 0.73 to 14.19 +/- 2.79 ng/ml. Phase 2 was characterized by moderately elevated pulmonary vascular pressures and a maintained high flow rate of protein-rich lymph. Lung lymph and plasma PGF2 alpha concentrations returned to base line. Lymph PGI2 decreased significantly to 5.23 +/- 2.47 ng/ml, whereas plasma PGI2 decreased to 2.70 +/- 1.07 ng/ml. We conclude that prostaglandins, particularly PGF2 alpha and prostacyclin, are released from the lung after endotoxemia and appear in lung lymph as sensitive indicators of pulmonary microvascular injury. Prostanoid production appears to temporally correspond with changes in the pulmonary microcirculation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7011057     DOI: 10.1152/ajpheart.1981.240.3.H348

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  24 in total

1.  Experimental studies on the effect of total thoracic esophagectomy on cardiorespiratory functions and the plasma concentration of chemical mediators.

Authors:  M Ideguchi
Journal:  Jpn J Surg       Date:  1991-01

2.  Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study.

Authors:  Arnaldo Dubin; Gastón Murias; Juan Pablo Sottile; Mario Omar Pozo; Marcelo Barán; Vanina Siham Kanoore Edul; Héctor Saúl Canales; Graciela Etcheverry; Bernardo Maskin; Elisa Estenssoro
Journal:  Intensive Care Med       Date:  2007-01-30       Impact factor: 17.440

Review 3.  The role of mediators in the response to thermal injury.

Authors:  Y K Youn; C LaLonde; R Demling
Journal:  World J Surg       Date:  1992 Jan-Feb       Impact factor: 3.352

Review 4.  Prostaglandins and the lung.

Authors:  S P Hanley
Journal:  Lung       Date:  1986       Impact factor: 2.584

5.  Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats.

Authors:  S W Chang; C O Feddersen; P M Henson; N F Voelkel
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

6.  Staphylococcal alpha-toxin elicits hypertension in isolated rabbit lungs. Evidence for thromboxane formation and the role of extracellular calcium.

Authors:  W Seeger; M Bauer; S Bhakdi
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

7.  Inhibition of pulmonary thromboxane A2 synthase activity and airway responses by CGS 13080.

Authors:  D B McNamara; J K Harrington; J A Bellan; G B Graybar; D C Underwood; P J Kadowitz
Journal:  Mol Cell Biochem       Date:  1989-01-23       Impact factor: 3.396

8.  Effects of indomethacin on prostaglandin E2 and thromboxane B2 contents of tracheal lavage fluids in premature infants.

Authors:  J C Le Guennec; M Lauzière; R Black; P Sirois
Journal:  Inflammation       Date:  1991-02       Impact factor: 4.092

9.  Multiple organ failure--a role for plasma exchange?

Authors:  P McClelland; P S Williams; M Yaqoob; S M Mostafa; J M Bone
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

10.  The inhibitory effect of aspirin on lymphatic contractility.

Authors:  J M Allen; E P Burke; M G Johnston; N G McHale
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.